Table 2 Effect of the antibiotic stewardship program intervention on the clinical success, microbiological success and 28-day all cause mortality rates in patients treated with tigecycline in different subgroups

Overall rate in all cases

74/153 (48.4%)

76/116 (65.5%)

0.005

69/153 (45.1%)

24/116 (20.7%)

< 0.0001

FDA approved indication

19/29 (65.5%)

67/91 (73.6%)

0.4

5/29 (17.2%)

15/91 (16.5%)

0.92

 cSSTI

10/18 (55.5%)

44/56 (78.6%)

0.06

4/18 (22.2%)

9/56 (16.1%)

0.55

 cIAI

3/4 (75%)

21/33 (63.6%)

1

0/4

6/33 (18.2%)

1

 CAP

6/8 (75%)

2/2 (100%)

1

2/8 (25%)

0/2

0.43

Off-label indication

55/124 (44.4%)

9/25 (36%)

0.16

64/124 (51.6%)

9/25 (36%)

0.15

 HAP

10/30 (33.3%)

0/6

0.56

22/30 (73.3%)

3/6 (50%)

0.34

 VAP

12/40 (30%)

0/4

0.441

24/40 (60%)

1/4 (25%)

0.3

 BSI

8/14 (57.1%)

0/0

NA

5/14 (35.7%)

0/0

NA

 Sepsis

1/13 (7.7%)

0/3

1

12/13 (%)

3/3 (100%)

1

 UTI

5/6 (83.3%)

1/2 (50%)

0.46

1/6 (16.7%)

0/2

1

 FN

21/24 (87.5%)

1/1 (100%)

1

3/24 (12.5%)

0/1

1

 Diabetic ulcer

5/8 (62.5%)

7/8 (87.5%)

0.57

1/8 (12.5%)

1/8 (12.5%)

1